- cafead   Aug 16, 2024 at 11:42: AM
via Incyte has announced positive topline data from the Phase III inMIND trial evaluating its CD19-targeting monoclonal antibody Monjuvi (tafasitamab) in patients with relapsed or refractory (r/r) follicular lymphoma.
article source
article source